Azitra (AZTR) Preferred Stock Liabilities (2022 - 2023)
Azitra (AZTR) reported Preferred Stock Liabilities of $3.3 million for Q1 2023, little changed quarter-over-quarter from $3.3 million in Q4 2022.
Azitra (AZTR) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends
Azitra has reported Preferred Stock Liabilities for 2 years, with the latest figure at $3.3 million in Q1 2023.
- For the quarter ending Q1 2023, Preferred Stock Liabilities changed N/A year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2023 stood at $3.3 million (changed N/A YoY), and the FY2022 full-year result was $3.3 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q1 2023 stood at $3.3 million, roughly flat from $3.3 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $3.3 million in Q4 2022, with the low at $3.3 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Azitra | 20,900.00 | 20,900.00 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 3.27 Mn |
| Dec 31, 2022 | 3.27 Mn |